当前位置: X-MOL 学术Expert Rev. Clin. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
In search of pathobiological endotypes: a systems approach to early rheumatoid arthritis.
Expert Review of Clinical Immunology ( IF 4.4 ) Pub Date : 2020-05-27 , DOI: 10.1080/1744666x.2020.1771183
Jessica R Tarn 1 , Dennis W Lendrem 1 , John D Isaacs 1
Affiliation  

Introduction

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease. Early referral and treatment are key to the effective management of the disease. This makes imperative the identification of biomarkers and of pathobiological endotypes.

Areas covered

This review describes recent efforts to integrate large-scale datasets for the identification of disease endotypes for precision medicine in early, seropositive RA. We conducted a search for systems and multi-omics papers in early RA patients through to 1 January 2020. We reviewed investigations of multiple technologies such as transcriptomic, proteomic and metabolomic platforms as well as extensive clinical datasets. We outline progress made and describe some of the advantages and limitations of current computational and statistical methods.

Expert opinion

The search for pathobiological endotypes in early RA is rapidly developing. While currently, studies tend to be small, reliant upon new technologies and unproven analytical tools, as the technology becomes cheaper and more reliable, and the properties of analytical tools for the integration of cross-platform biology become better understood, it seems likely that better biomarkers of disease, remission and response to individual therapies will emerge.



中文翻译:

寻找病理生物学内型:早期类风湿性关节炎的系统方法。

简介

类风湿性关节炎 (RA) 是一种慢性、全身性自身免疫性疾病。早期转诊和治疗是有效管理疾病的关键。这使得生物标志物和病理生物学内型的鉴定势在必行。

覆盖区域

这篇综述描述了最近整合大规模数据集的努力,用于识别早期血清阳性 RA 的精准医学疾病内型。我们对早期 RA 患者的系统和多组学论文进行了搜索,直到 2020 年 1 月 1 日。我们审查了多项技术的研究,例如转录组学、蛋白质组学和代谢组学平台以及广泛的临床数据集。我们概述了取得的进展并描述了当前计算和统计方法的一些优点和局限性。

专家意见

对早期 RA 病理生物学内型的研究正在迅速发展。虽然目前的研究规模较小,依赖于新技术和未经证实的分析工具,但随着技术变得更便宜、更可靠,以及对跨平台生物学整合的分析工具的特性得到更好的理解,似乎可能会更好疾病、缓解和对个体治疗反应的生物标志物将会出现。

更新日期:2020-07-21
down
wechat
bug